Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COLUMN
COLUMN
- Rare Disease Pharmaceuticals in Japan to See New Demand for Skilled Human Resources
July 20, 2018
- 5 Billion Yen Blockbuster?
June 20, 2018
- It Is Thumbs Up for Cell Therapy in Japan
March 23, 2018
- Unique Opportunities at Pharmaceutical Companies Treating Rare Diseases
February 23, 2018
- When Leading Teams, Focus on the Principles, Not the Personalities
January 26, 2018
- What to Do about the Feeling of Torschlusspanik?
October 27, 2017
- Women! Rock the Boat and Get Promoted
September 22, 2017
- Getting the Right Message
August 25, 2017
- Putting on Your Pants
July 21, 2017
- Reputable Combination
July 11, 2017
- What Is the Best Path to Customers’ Hearts and Minds?
June 19, 2017
- Doubling Down on Digital
May 26, 2017
- Global Opportunities for Global Minds
April 21, 2017
- Will Tepid Pricing Debate Only Go Full-Throttle after Golden Week Holidays?
March 30, 2017
- Some Japanese Pharmaceutical Workers May Slowly Be Working Themselves to Death
March 17, 2017
- The Best Recruiters Are Just a Little Paranoid
February 17, 2017
- 5 Killer Questions for HR to Ask Recruiters
January 20, 2017
- What Pharma Can Learn from the Airline Industry
December 16, 2016
- Near Death at Singapore General Hospital and 5 Lessons I Learnt
October 20, 2016
- Reasons for a “Hold”
August 9, 2016
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…